Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11064389 | 0.78 | TLR8 (0.37) | TLR8 | |
| SCHEMBL9899998 | 0.76 | TLR8 (0.35) | TLR8 | |
| SCHEMBL31227392 | 0.76 | TLR8 (0.53) | TLR8 | |
| SCHEMBL181124 | 0.74 | TLR8 (0.34) | TLR8 | |
| SCHEMBL23124290 | 0.73 | TLR8 (0.36) | TLR8 | |
| SCHEMBL30644495 | 0.73 | ALOX15 (0.36) | TLR8 | |
| SCHEMBL954122 | 0.73 | TLR8 (0.33) | TLR8 | |
| SCHEMBL27243847 | 0.72 | IDH1 (0.36) | TLR8 | |
| SCHEMBL30881399 | 0.72 | IDH1 (0.36) | TLR8 | |
| SCHEMBL16877109 | 0.72 | GAA (0.33) | TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4596550-A1 | COMPOUND USABLE IN CONJUGATION REACTION AND CONJUGATE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024114528-A9 | COMPOUND USABLE IN CONJUGATION REACTION AND CONJUGATE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-10-03 | — | — | WO | disclosed |
| US-20240252665-A1 | CHEMICAL COUPLING LINKER AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-08-01 | — | — | US | disclosed |
| WO-2024114528-A1 | COMPOUND USABLE IN CONJUGATION REACTION AND CONJUGATE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-06-06 | — | — | WO | disclosed |
| EP-4349832-A1 | CHEMICAL COUPLING LINKER AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2024-04-10 | — | — | EP | disclosed |
| CN-117255790-A | Chemical coupling connector and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| WO-2022253033-A1 | CHEMICAL COUPLING LINKER AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| US-10202391-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2019-02-12 | — | — | US | disclosed |
| EP-3374359-A1 | DIHYDROIMIDAZOPYRAZINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2018-09-19 | — | — | EP | disclosed |
| US-20180237443-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2018-08-23 | — | — | US | disclosed |
| US-9902731-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2018-02-27 | — | — | US | disclosed |
| US-20170204100-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2017-07-20 | — | — | US | disclosed |
| WO-2017080979-A1 | DIHYDROIMIDAZOPYRAZINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2017-05-18 | — | — | WO | disclosed |
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-8796314-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20100256172-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| EP-2214673-A1 | NOVEL PHENYL-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | Boehringer Ingelheim International GmbH (DE) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009053268-A1 | NOVEL PHENYL-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202391-B2 | Chemical compounds | TP53, RB1, ABCB1 | TLR8 4690/4885 |
| US-20240252665-A1 | CHEMICAL COUPLING LINKER AND USE THEREOF | VIP, PAICS, BCR | TLR8 1029/4885 |
| US-20170204100-A1 | Chemical Compounds | TP53, RB1, ABCB1 | TLR8 4690/4885 |
| US-20180237443-A1 | Chemical Compounds | TP53, RB1, ABCB1 | TLR8 4690/4885 |
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | TLR8 3152/4885 |
| US-20100256172-A1 | Heteroaryls and uses thereof | PIK3R3, PIK3R1, AKT3 | TLR8 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.